Background/Aims: To evaluate the efficacy and safety of adalimumab (ADA) in moderately to severely active @entity31 ( @entity31 ) @entity1 who are unresponsive to traditional therapy. Methods: Electronic databases, including the PubMed, Embase, and Cochrane databases, were searched to April 20, 2014. @entity31 -related @entity23 ( @entity23 ) that compared ADA with placebo were eligible. Review Manager 5.1 was used for data analysis. Results: This meta-analysis included three @entity23 . ADA was considerably more effective compared with a placebo, and it increased the ratio of @entity1 with clinical remission, clinical responses, @entity33 and @entity29 questionnaire responses in the induction and maintenance phases (p<0.05), as well as @entity1 with steroid-free remission (p<0.05) during the maintenance phase. Clinical remission was achieved in a greater number of @entity31 cases in the ADA 160/80/40 mg groups (0/2/4 week, every other week) compared with the placebo group at week 8 (p=0.006) and week 52 (p=0.0002), whereas the week 8 clinical remission rate was equivalent between the ADA 80/40 mg groups and the placebo group. Among the @entity1 who received immunomodulators (IMM) at baseline, ADA was superior to the placebo in terms of inducing clinical remission (p=0.01). Between-group differences were not observed in terms of serious adverse events (p=0.61). Conclusions: ADA, particularly at doses of 160/80/40 mg (0/2/4 week, every other week), is effective and safe in @entity1 with moderate-to-severe @entity31 who are unresponsive to traditional treatment. Concomitant IMM therapy may improve the short-term therapeutic efficacy of ADA.

Efficacy and Safety of Adalimumab in Moderately to Severely Active Cases of XXXX : A Meta-Analysis of Published Placebo-Controlled Trials.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity31 :: ('MESH:D003093', 'Disease') :: ['ulcerative colitis', 'UC'] @entity33 :: ('MESH:D052016', 'Disease') :: ['mucosal healing'] @entity29 :: ('MESH:D015212', 'Disease') :: ['inflammatory bowel disease'] @entity23 :: ('MESH:D007174', 'Disease') :: ['randomized controlled trials', 'RCTs']
@entity31 :: (MESH:D003093,Disease) :: ['Ulcerative Colitis']
